Simon Erickson Archives - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Posts by Simon Erickson

Article

ASML is About to Have a Monster Year; Upgrading Our…

Jul 2, 2024

The Dutch lithography equipment supplier looks like it'll be very busy in the second half of 2024.

Article

Cassava Sciences: Is The Fraud Investigation Just Smoke…or an Actual…

Jul 1, 2024

This micro-cap biotech company is working on an innovative cure to Alzheimer's Disease but is surrounded by controversy. Is it worth the risk for investors?

Premium Advisor Update

Simon’s June 2024 Conviction Rating Review

Jun 15, 2024

Article

Illumina Officially Ends Its Quest for the Holy GRAIL

Jun 7, 2024

After feeling the heat from investors, customers, and regulators, Illumina has finally agreed to divest GRAIL.

Article

Tesla “the AI Company” is Worth $645 Per Share. Here’s…

May 21, 2024

If Tesla executes on its FSD ambitions, the rewards for investors could be massive.

Premium Advisor Update

Simon’s May 2024 Conviction Rating Review

May 15, 2024

Article

Tesla “the Car Company” is Worth $104 Per Share. Here’s…

May 14, 2024

Tesla's stock has a lot riding on its FSD future. Will Elon successfully navigate the opportunity?

Article

Tesla’s Growth Will Accelerate Into 2030

May 9, 2024

Despite some near-term speedbumps, strong global demand for EVs should accelerate Tesla's vehicle sales through 2030.

Article

5 Key Takeaways Investors Should Know About Tesla

May 7, 2024

The EV innovator is facing some near-term headwinds, but is still full-speed ahead when it comes to global expansion.

Article

What’s Tesla Really Worth? Now’s the Right Time to Find…

May 6, 2024

How much is Tesla's stock really worth? 7investing CEO Simon Erickson will be answering one of investing's biggest questions this week.

Article

The Trade Desk is Worth $62 Per Share. Here’s Why.

Apr 25, 2024

Is the stock of this digital advertising innovator significantly overpriced? We dug deep and let the numbers do the talking.

Premium Advisor Update

Simon’s April 2024 Conviction Rating Review

Apr 15, 2024

Article

Coupang is Worth $19.25 Per Share, But With Hidden Upside.…

Apr 12, 2024

The base case of my Discounted Cash Flow predicts Coupang's stock is currently worth $19.25 per share. But like we saw this morning, it also has some excellent hidden optionality.

Podcast

ShockWave Medical Receives a Buyout Offer

Apr 8, 2024

Shockwave Medical (Nasdaq: SWAV), the innovative leader in intravascular lithotripsy, has received a $335 per share all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ). 

Article

Contest Matchup #6: CRISPR Therapeutics vs Seres Therapeutics

Apr 2, 2024

Two biotech companies go head-to-head in our sixth Stockpicking matchup.

Article

Contest Matchup #5: Intel vs Super Micro Computer

Mar 28, 2024

Two semiconductor companies go head-to-head in the fifth of our Stockpicking matchups.

Article

Rocket Lab’s Stock is Worth $22 and has 453% Upside.…

Mar 21, 2024

My Discounted Cash Flow analysis calculates that Rocket Lab's stock is worth $22.35 per share. That represents 453% upside from today's current price, making it one of the stock market's most...

Podcast

Searching for Value with John Rotonti

Mar 14, 2024

Premium Advisor Update

Simon’s March 2024 Conviction Rating Review

Mar 14, 2024

Article

Contest Matchup #3: The Trade Desk vs Palantir

Mar 12, 2024

Two smart companies who are embracing AI to become even smarter. Which will be the wiser investment for 2024?

Article

Contest Matchup #2: Uber vs Rocket Lab

Mar 6, 2024

In our second of seven Stockpicking Challenge matchups, the mover of people squares up against the mover of satellites.

Article

Contest Matchup #1: Celsius Holdings vs Novo Nordisk

Mar 4, 2024

In our first of seven Stockpicking Challenge matchups, the energy drink maker squares up against the weight-loss drug manufacturer.

Article

3 Takeaways from the 2024 WSJ Health Forum

Feb 27, 2024

The WSJ Health Forum showcased several new technologies and industry-wide discussions. Here were three of its biggest highlights.

Article

3 Emerging Technologies Investors Should Be Watching

Feb 26, 2024

The 2023 MIT EmTech conference showcased three important new technologies in climate tech, health care, and generative AI.

Article

Krystal Biotech is Soaring. But the Good Times Are Just…

Feb 26, 2024

The small-cap biotech company just reported excellent 4Q results. But there might be even more gains on the horizon.

Premium Advisor Update

My Complete Notes from the 2024 WSJ Health Forum

Feb 22, 2024